×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
RIGL – rigel pharmaceuticals, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
RIGL
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
2/3
08:33 am
rigl
Rigel Appoints Michael P. Miller to the Board of Directors [Yahoo! Finance]
Low
Report
Rigel Appoints Michael P. Miller to the Board of Directors [Yahoo! Finance]
2/3
08:05 am
rigl
Rigel Appoints Michael P. Miller to the Board of Directors
Low
Report
Rigel Appoints Michael P. Miller to the Board of Directors
1/26
10:47 pm
rigl
Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026 [Seeking Alpha]
Low
Report
Rigel Pharmaceuticals: Continued Financial Performance, Catalysts In 2026 [Seeking Alpha]
1/22
07:48 am
rigl
Rigel Pharmaceuticals (NASDAQ:RIGL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "strong sell" rating.
Low
Report
Rigel Pharmaceuticals (NASDAQ:RIGL) was downgraded by analysts at Zacks Research from a "strong-buy" rating to a "strong sell" rating.
1/20
11:31 am
rigl
How The Narrative Around Rigel Pharmaceuticals (RIGL) Is Shifting With Raised Guidance And Cash Flow [Yahoo! Finance]
Low
Report
How The Narrative Around Rigel Pharmaceuticals (RIGL) Is Shifting With Raised Guidance And Cash Flow [Yahoo! Finance]
1/16
03:41 am
rigl
Is Rigel Pharmaceuticals (RIGL) 2026 Revenue Guidance Reframing Its Commercial-Led Investment Narrative? [Yahoo! Finance]
Low
Report
Is Rigel Pharmaceuticals (RIGL) 2026 Revenue Guidance Reframing Its Commercial-Led Investment Narrative? [Yahoo! Finance]
1/14
06:04 am
rigl
Rigel Pharmaceuticals (NASDAQ:RIGL) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Rigel Pharmaceuticals (NASDAQ:RIGL) had its "buy" rating reaffirmed by analysts at Citigroup Inc..
1/12
08:32 am
rigl
Rigel Provides Business Update and 2026 Outlook [Yahoo! Finance]
Medium
Report
Rigel Provides Business Update and 2026 Outlook [Yahoo! Finance]
Date
Time
Symbol
Company Name
Action
%Chg
11/4/2025
04:01 pm
rigl
rigel pharmaceuticals, inc.
BEAT
Report
33.4%
rigel pharmaceuticals, inc.
8/5/2025
04:01 pm
rigl
rigel pharmaceuticals, inc.
BEAT
Report
23.0%
rigel pharmaceuticals, inc.
5/6/2025
04:01 pm
rigl
rigel pharmaceuticals, inc.
BEAT
Report
1.2%
rigel pharmaceuticals, inc.
3/4/2025
04:01 pm
rigl
rigel pharmaceuticals, inc.
BEAT
Report
-8.1%
rigel pharmaceuticals, inc.
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
2/4
04:22 pm
rigl
Form 4 RIGEL PHARMACEUTICALS For: Feb 02 Filed by: Santos David A
Medium
Report
Form 4 RIGEL PHARMACEUTICALS For: Feb 02 Filed by: Santos David A
2/4
04:21 pm
rigl
Form 4 RIGEL PHARMACEUTICALS For: Feb 02 Filed by: Schorno Dean L
Medium
Report
Form 4 RIGEL PHARMACEUTICALS For: Feb 02 Filed by: Schorno Dean L
2/4
04:21 pm
rigl
Form 4 RIGEL PHARMACEUTICALS For: Feb 02 Filed by: Furey Raymond J.
Medium
Report
Form 4 RIGEL PHARMACEUTICALS For: Feb 02 Filed by: Furey Raymond J.
2/4
04:20 pm
rigl
Form 4 RIGEL PHARMACEUTICALS For: Jan 26 Filed by: RODRIGUEZ RAUL R
Medium
Report
Form 4 RIGEL PHARMACEUTICALS For: Jan 26 Filed by: RODRIGUEZ RAUL R
2/3
04:10 pm
rigl
Form 4 RIGEL PHARMACEUTICALS For: Feb 01 Filed by: MILLER MICHAEL PATRICK
Medium
Report
Form 4 RIGEL PHARMACEUTICALS For: Feb 01 Filed by: MILLER MICHAEL PATRICK
2/3
04:05 pm
rigl
Form 3 RIGEL PHARMACEUTICALS For: Feb 01 Filed by: MILLER MICHAEL PATRICK
Medium
Report
Form 3 RIGEL PHARMACEUTICALS For: Feb 01 Filed by: MILLER MICHAEL PATRICK
2/3
04:01 pm
rigl
Form 8-K RIGEL PHARMACEUTICALS For: Feb 01
Medium
Report
Form 8-K RIGEL PHARMACEUTICALS For: Feb 01
1/12
08:15 am
rigl
Form 8-K RIGEL PHARMACEUTICALS For: Jan 12
Medium
Report
Form 8-K RIGEL PHARMACEUTICALS For: Jan 12
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
1/13
Form 8-K RIGEL PHARMACEUTICALS For: Jan 13
20.0%
10/23 Here's Why Rigel Pharmaceuticals Stock Jumped as Much as 10.7% Today [The Motley Fool] 17.1%
4/27 Rigel Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update 9.0%
2/27 Rigel Pharmaceuticals, Inc. 2019 Q4 - Results - Earnings Call Presentation [Seeking Alpha] 6.5%
6/28 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 6.5%
3/4 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.4%
5/23 Form 4 RIGEL PHARMACEUTICALS For: May 22 Filed by: Schorno Dean L 5.9%
5/21 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.9%
9/23 Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia 5.1%
8/6 Q2/2019 6/30/2019 EPS -0.120 ZacksConsensus -0.140 ActVsEst 0.020 - Beat 4.6%
10/23 Here's Why Rigel Pharmaceuticals Stock Jumped as Much as 10.7% Today [The Motley Fool] 17.1%
4/27 Rigel Announces Conference Call and Webcast to Report First Quarter 2020 Financial Results and Business Update 9.0%
2/27 Rigel Pharmaceuticals, Inc. 2019 Q4 - Results - Earnings Call Presentation [Seeking Alpha] 6.5%
6/28 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. 6.5%
3/4 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. 6.4%
5/23 Form 4 RIGEL PHARMACEUTICALS For: May 22 Filed by: Schorno Dean L 5.9%
5/21 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 5.9%
9/23 Rigel's fostamatinib Enters Phase 3 Clinical Trial in Japan with Kissei Pharmaceuticals for the Treatment of Chronic Immune Thrombocytopenia 5.1%
8/6 Q2/2019 6/30/2019 EPS -0.120 ZacksConsensus -0.140 ActVsEst 0.020 - Beat 4.6%
TOP News Decliners
4/1
Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $1.75 price target on the stock.
-11.9%
11/6 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -9.9%
5/7 Form 8-K RIGEL PHARMACEUTICALS For: May 07 -7.4%
12/17 Rigel Announces Chief Commercial Officer Transition -6.4%
8/10 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $2.50 price target on the stock. -6.4%
4/30 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -5.8%
10/29 Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results -5.7%
5/1 Rigel Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders -5.5%
10/18 Rigel Pharma not quite there with European application for fostamatinib [Seeking Alpha] -4.9%
9/26 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $7.00 price target on the stock. -4.8%
11/6 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -9.9%
5/7 Form 8-K RIGEL PHARMACEUTICALS For: May 07 -7.4%
12/17 Rigel Announces Chief Commercial Officer Transition -6.4%
8/10 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "strong-buy" rating. They now have a $2.50 price target on the stock. -6.4%
4/30 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -5.8%
10/29 Rigel Announces Conference Call and Webcast to Report Third Quarter 2019 Financial Results -5.7%
5/1 Rigel Announces Change to Virtual Format for 2020 Annual Meeting of Stockholders -5.5%
10/18 Rigel Pharma not quite there with European application for fostamatinib [Seeking Alpha] -4.9%
9/26 Rigel Pharmaceuticals, Inc. (NASDAQ: RIGL) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $7.00 price target on the stock. -4.8%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: